RxDoctor Payments Data

Ayoola Gomih, MD

Urology · Merrillville, INNPI 1831117522

Payments from drug & device makers

What this record shows

This record is dominated by ownership interests: $16,088 of the $20,187 with a category attached, or 79.7%. Great Lakes Medical Services, LLC accounts for 83.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $9,984 and has fallen 92.2% since, to $777 in 2025.

$20,187in general payments, 2019–2025

Across 134 payments — averaging $150.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Great Lakes Medical Services, LLC$17K
  • Astellas Pharma US Inc$1K
  • Boston Scientific$586
  • Endo Pharmaceuticals Inc.$570
  • Pfizer$352
  • Endo USA, Inc.$188
  • plus $522 from 9 others

What the payments were for

  • Speaking & faculty fees$8294%
  • Travel & lodging$4602%
  • Food & beverage$2,16911%
  • Education$6413%
  • Ownership interest$16,08880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,187 in reported general payments places this provider in the 85th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Medicare billing

Part B allowed, 2024
$64,584
Medicare patients
260
Services billed
639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide49$511,767
OrgovyxRelugolix87$238,958
Lupron DepotLeuprolide Acetate15$91,106
MyrbetriqMirabegron80$72,090
Mirabegron ErMirabegron13$9,197
Bethanechol Chloride77$4,147
Tolterodine Tartrate ErTolterodine Tartrate16$2,803
Tamsulosin Hcl324$2,788
Oxybutynin Chloride ErOxybutynin Chloride75$2,755
Bicalutamide58$2,259
Finasteride210$2,099
Dutasteride37$1,061
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$703
Alfuzosin Hcl ErAlfuzosin Hcl37$470
Oxybutynin Chloride11$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,051$583,857129 claims
Sumitomo Pharma America, Inc.Orgovyx$137$238,95887 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 272 urology providers in Indiana.

Other urology in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →